On Friday, Shares of Exelixis, Inc. (NASDAQ:EXEL), subtract -4.95% and closed at $11.32 in the last trading session. The last trading range of the stock ranges between $11.31 and $12.08. Exelixis, Inc. (EXEL) recently declared detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with formerly untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Principal investigator Toni K. Choueiri, M.D. will present detailed data from late-breaking CABOSUN abstract [#LBA30_PR] recently in the Presidential Symposium 3 session, starting at 16:30 CEST (local Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT at the European Society for Medical Oncology (ESMO) 2016, which is being held October 7 – 11, 2016 in Copenhagen.
CABOSUN was conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis’ partnershipwith the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP).
In CABOSUN, with a median follow-up of 20.8 months, cabozantinib demonstrated a clinically meaningful and statistically noteworthy31 percent reduction in the rate of disease progression or death [HR 0.69, 95% CI (0.48-0.99), one-sided P=0.012]. The median progression-free survival (PFS) for cabozantinib was 8.2 months as compared to 5.6 months for sunitinib, corresponding to a 2.6 months (46 percent) improvement favoring cabozantinib over sunitinib. PFS benefits were independent of IMDC risk group (intermediate or poor risk) and presence or absence of bone metastases at baseline. The results for sunitinib were in line with a formerly published retrospective analysis of 1,174 intermediate- and poor-risk RCC patients from the IMDC database, which documented a median PFS of 5.6 months with a first-line targeted therapy, mainly sunitinib, in this patient population.1
Xerox Corp (NYSE:XRX), jumped 1.05% and closed at $9.65 in the last trading session. The last trading range of the stock ranges between $9.58 and $9.71. The company’s Market capitalization is $9.88 Billion with the total outstanding Shares of 1.01 billion. The U.S. Department of Agriculture (USDA) has awarded Xerox (XRX) a 10-year, $110M contract for managed print services (MPS) across all USDA agencies. As part of the agreement, Xerox will install and support up to 16,000 Xerox ConnectKey®-facilitated printers and multifunction devices at more than 3,000 USDA sites around the globe.
USDA is working with Xerox to reduce costs while creating a print, copy, fax and scan environment with fewer but more powerful devices and a smaller environmental footprint. New tools – like ready-to-use apps built into the interface – facilitated by the Xerox ConnectKey technology will support migration to digital workflows and provide detailed analytics to reduce print volumes and paper consumption.